These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 37174050)
21. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers. Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366 [TBL] [Abstract][Full Text] [Related]
23. Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Shrestha B; Sun Y; Faisal F; Kim V; Soares K; Blair A; Herman JM; Narang A; Dholakia AS; Rosati L; Hacker-Prietz A; Chen L; Laheru DA; De Jesus-Acosta A; Le DT; Donehower R; Azad N; Diaz LA; Murphy A; Lee V; Fishman EK; Hruban RH; Liang T; Cameron JL; Makary M; Weiss MJ; Ahuja N; He J; Wolfgang CL; Huang CY; Zheng L Cancer Med; 2017 Jul; 6(7):1552-1562. PubMed ID: 28639410 [TBL] [Abstract][Full Text] [Related]
24. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study. Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M; BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786 [TBL] [Abstract][Full Text] [Related]
25. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596 [TBL] [Abstract][Full Text] [Related]
26. Role of neoadjuvant therapy in the management of pancreatic cancer: is the era of biomarker-directed therapy here? Tsvetkova EV; Asmis TR Curr Oncol; 2014 Aug; 21(4):e650-7. PubMed ID: 25089113 [TBL] [Abstract][Full Text] [Related]
28. Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749). Tachezy M; Gebauer F; Petersen C; Arnold D; Trepel M; Wegscheider K; Schafhausen P; Bockhorn M; Izbicki JR; Yekebas E BMC Cancer; 2014 Jun; 14():411. PubMed ID: 24906700 [TBL] [Abstract][Full Text] [Related]
29. Current standards and new innovative approaches for treatment of pancreatic cancer. Conroy T; Bachet JB; Ayav A; Huguet F; Lambert A; Caramella C; Maréchal R; Van Laethem JL; Ducreux M Eur J Cancer; 2016 Apr; 57():10-22. PubMed ID: 26851397 [TBL] [Abstract][Full Text] [Related]
30. Preoperative ultrasound ablation for borderline resectable pancreatic cancer: A report of 30 cases. Wang G; Zhou D Ultrason Sonochem; 2015 Nov; 27():694-702. PubMed ID: 26113389 [TBL] [Abstract][Full Text] [Related]
31. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. Keane FK; Wo JY; Ferrone CR; Clark JW; Blaszkowsky LS; Allen JN; Kwak EL; Ryan DP; Lillemoe KD; Fernandez-Del Castillo C; Hong TS Am J Clin Oncol; 2018 Jun; 41(6):607-612. PubMed ID: 27740973 [TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant Treatment for Pancreatic Cancer. Raufi AG; Manji GA; Chabot JA; Bates SE Semin Oncol; 2019 Feb; 46(1):19-27. PubMed ID: 30630600 [TBL] [Abstract][Full Text] [Related]
33. Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation. Amodeo S; Masi A; Melis M; Ryan T; Hochster HS; Cohen DJ; Chandra A; Pachter HL; Newman E J Gastrointest Oncol; 2018 Oct; 9(5):922-935. PubMed ID: 30505595 [TBL] [Abstract][Full Text] [Related]
34. Borderline resectable pancreatic cancer: Certainties and controversies. Nappo G; Donisi G; Zerbi A World J Gastrointest Surg; 2021 Jun; 13(6):516-528. PubMed ID: 34194610 [TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre. Roselló S; Pizzo C; Huerta M; Muñoz E; Aliaga R; Vera A; Alfaro-Cervelló C; Jordá E; Garcés-Albir M; Roda D; Dorcaratto D; Tarazona N; Torondel S; Guijarro J; Sánchiz V; Gambardella V; Fleitas-Kanonnikoff T; Lluch P; Pascual I; Ferrández A; Sabater L; Cervantes A ESMO Open; 2020 Nov; 5(6):e000929. PubMed ID: 33229503 [TBL] [Abstract][Full Text] [Related]
36. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update. Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639 [TBL] [Abstract][Full Text] [Related]